Anecdotally, there are reports of low uptake of whole genome sequencing across different regions in England, citing challenges in implementing pathways to enable WGS, or a lack of education and training opportunities as the main factors.

TOPICS COVERED

Attendance at the morning sessions will enable people to:

• Compare the application of whole genome sequencing in solid tumours and haematological malignancies in paediatric cancer patients in the UK to existing testing strategies.
• Summarise the process for implementing whole genome sequencing at a local/regional level.

The first part of this three hour session will cover the impact of whole genome sequencing in paediatric oncology, the strategic goals of NHS England and the impact and use of WGS to pathology practice. The next session will provide exemplars of how WGS is being used in UK and international centres. The morning will end with an open discussion, led by Parker Moss from Genomics England.

WHO SHOULD ATTEND?

Anyone with an interest in how whole genome sequencing can be used in paediatric oncology. This may include pathologists and clinical scientists.

SPEAKERS

• Professor Dame Sue Hill, CSO for England and SRO for Genomics in NHS England.
• Parker Moss, Genomics England
• Dr Sarah Bowdin, NHS East Genomic Laboratory Hub
• Dr David Bentley & Dr Mark Ross, Illumina Cambridge
• Dr Liz Hook, University Of Cambridge and Cambridge University Hospitals NHS Foundation Trust
• Dr Jack Bartram, Great Ormond Street Hospital
• Dr Sam Behjati, Wellcome Sanger Institute and Cambridge University Hospitals NHS Foundation Trust.
• Dr Ruth Armstrong, East Anglian Medical Genetics Service
• Dr Brian Chung, Hong Kong Genome Institute and the University of Hong Kong.